

Mail Stop 6010

June 17, 2008

A.J. Kazimi  
Chairman and Chief Executive Officer  
Cumberland Pharmaceuticals Inc.  
2525 West End Avenue, Suite 950  
Nashville, Tennessee 37203

**Re: Cumberland Pharmaceuticals Inc.  
Amendment No. 11 to Registration Statement on Form S-1/A  
Filed June 9, 2008  
File No. 333-142535**

Dear Mr. Kazimi:

We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with supplemental information so we may better understand your disclosure. After reviewing this information, we may or may not raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

Amendment No. 11 to Registration Statement on Form S-1/A

Management's Discussion and Analysis of Financial Condition and Results of Operations

Critical Accounting Policies and Significant Judgments and Estimates

Stock-Based Compensation, page 33

1. You disclose that one of the factors in establishing the fair value of your common stock is the review of third-party valuation reports secured from time to time by management. Please name the third party that provided valuation reports to management and provide their consent in the registration statement. If Morgan Joseph & Co. Inc. provided the third-party valuation reports, please clarify your disclosure and provide a currently dated consent from this firm.

Business

International Sales and Marketing, page 59

2. Please disclose the aggregate potential milestone payments receivable pursuant to your agreements with Alveda Pharmaceuticals, Hospira Singapore, and Phebra.

Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm, page F-2

3. The report of KPMG LLP is missing a signature. Please have KPMG LLP revise their report to include a signature as required by Rule 2-02(a) of Regulation S-X.

\* \* \* \* \*

As appropriate, please amend your filing in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested supplemental information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings reviewed by the staff to be certain that they have provided all information investors require for an informed decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

Notwithstanding our comments, in the event the company requests acceleration of the effective date of the pending registration statement, it should furnish a letter, at the time of such request, acknowledging that:

A.J. Kazimi  
Cumberland Pharmaceuticals Inc.  
June 17, 2008  
Page 3

- should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
- the company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in connection with our review of your filing or in response to our comments on your filing.

We will consider a written request for acceleration of the effective date of the registration statement as a confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the above registration statement. We will act on the request and, pursuant to delegated authority, grant acceleration of the effective date.

We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow adequate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in advance of the requested effective date.

You may contact Donald Abbott at (202) 551-3608 if you have questions regarding comments on the financial statements and related matters. Please contact Rose Zukin at (202) 551-3239, Suzanne Hayes at (202) 551-3675, or me at (202) 551-3715 with any other questions.

Sincerely,

Jeffrey P. Riedler  
Assistant Director

cc: Martin S. Brown, Esq.  
Adams and Reese LLP  
424 Church Street, Suite 2800  
Nashville, Tennessee 37219